VRAX 6-K SEC Filing Analysis

Latest settled — T+5d

VRAX ▼ -21.15% at T+5d

LONG call ✗ call lost -21.15% · α vs SPY -22.23% · entry $0.2270 → $0.1790

Next anchor: T+20d in 14d

Last close $0.2090 (close Jun 8) · -7.93% from $0.2270 entry

Entry anchored
May 26, 07:32 AM ET
via Databento tick

T+1d

-3.52%

call -3.52% · α -3.54%

$0.2190

settled 14d ago

T+5d

-21.15%

call -21.15% · α -22.23%

$0.1790

settled 8d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Virax Biolabs reported early pilot data for its ViraxImmune blood-based test for Long COVID and related post-acute infection syndromes, showing 88% specificity and 92% positive predictive value in a small pilot dataset. The test has been evaluated in over 120 subjects, with a larger 300-participant validation analysis expected to begin in Q4 2026 with results in Q1 2027. The company is pursuing a U.S. Laboratory Developed Test route to market, but ViraxImmune is not yet approved for diagnostic use in any jurisdiction.

Actionable Insight

Positive early pilot data for ViraxImmune provides a potential catalyst for VRAX, but the test remains in early development with no regulatory approval. Monitor for the larger 300-subject validation results expected in Q1 2027 and any partnership or regulatory developments. The $2M market cap suggests high risk; position sizing should reflect binary outcome risk.

Key Facts

ViraxImmune pilot data showed 88% specificity and 92% positive predictive value in separating PAIS patients from healthy controls
Test evaluated in more than 120 subjects in ongoing UK clinical study
Larger validation study of 300 additional participants planned for Q4 2026 with results expected Q1 2027
Company pursuing U.S. Laboratory Developed Test route to market
Virax estimates up to 21 million U.S. adults may have Long COVID or related PAIS conditions, with 2.5 million new cases per year
ViraxImmune is not approved for diagnostic use in any jurisdiction

Financial Impact

No financial figures reported; pre-revenue clinical-stage company with $2M market cap

Risk Factors

ViraxImmune is not approved for diagnostic use and may never receive regulatory clearance
Pilot data is preliminary and may not replicate in larger validation studies
Company has $2M market cap with no disclosed revenue, indicating high cash burn risk and potential dilution
Long COVID diagnostic market is competitive with multiple players developing similar tests
Results from larger study not expected until Q1 2027, creating extended period of binary uncertainty

Market Snapshot

Exchange

Nasdaq

Sector

In Vitro & In Vivo Diagnostic Substances

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001193125-26-237882
Document: vrax-ex99_1.htm	0001193125-26-237882
Document: 0001193125-26-237882-index-headers.html	0001193125-26-237882
Document: 0001193125-26-237882.txt	0001193125-26-237882

2 reports for VRAX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for VRAX — sortable, filterable
	Type				Now
May 26, 2026 14d ago	6-K BULLISH ★ 6/10	$0.2270 $0.1790	▼ −21.15%	▼ −22.23%	$0.2090 (−7.93%)
Apr 10, 2026 8w ago	6-K BEARISH ★ 6/10	$0.1660 $0.1420	▲ +14.46%	▲ +17.75%	$0.2090 (−25.90%)

US Market Status

Market Closed — Opens in 7h 26m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access